Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.36
+0.02 (0.37%)
At close: Apr 28, 2026, 4:00 PM EDT
5.37
+0.01 (0.19%)
After-hours: Apr 28, 2026, 4:47 PM EDT
Abeona Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 5.82 | - | 3.5 | 1.41 | 3 | |
| Revenue Growth (YoY) | - | - | 147.53% | -52.87% | -70.00% | |
| Cost of Revenue | 30.24 | 34.36 | 32.7 | 29.42 | 38.73 | |
| Gross Profit | -24.42 | -34.36 | -29.2 | -28 | -35.73 | |
| Selling, General & Admin | 65.03 | 29.85 | 19 | 17.26 | 21.64 | |
| Operating Expenses | 65.03 | 29.85 | 19 | 17.26 | 21.64 | |
| Operating Income | -89.45 | -64.21 | -48.2 | -45.26 | -57.37 | |
| Interest Expense | -3.74 | -4.21 | -0.42 | -0.74 | -3.66 | |
| Interest & Investment Income | 5.56 | 4.25 | 2.12 | 0.43 | 0.04 | |
| Other Non Operating Income (Expenses) | 6.55 | 0.44 | -8.71 | 11.66 | 0.02 | |
| EBT Excluding Unusual Items | -81.08 | -63.74 | -55.21 | -33.9 | -60.97 | |
| Impairment of Goodwill | - | - | - | - | -32.47 | |
| Gain (Loss) on Sale of Assets | 152.37 | 0 | -0.05 | -0.14 | - | |
| Asset Writedown | - | - | 1.07 | -5.66 | - | |
| Other Unusual Items | - | - | - | - | 8.5 | |
| Pretax Income | 71.28 | -63.73 | -54.19 | -39.7 | -84.94 | |
| Income Tax Expense | 0.1 | - | - | - | - | |
| Net Income | 71.18 | -63.73 | -54.19 | -39.7 | -84.94 | |
| Preferred Dividends & Other Adjustments | - | - | - | 3.78 | - | |
| Net Income to Common | 71.18 | -63.73 | -54.19 | -43.48 | -84.94 | |
| Shares Outstanding (Basic) | 53 | 41 | 21 | 8 | 4 | |
| Shares Outstanding (Diluted) | 66 | 41 | 21 | 8 | 4 | |
| Shares Change (YoY) | 61.12% | 91.99% | 171.96% | 99.65% | 6.24% | |
| EPS (Basic) | 1.34 | -1.55 | -2.53 | -5.53 | -21.57 | |
| EPS (Diluted) | 1.01 | -1.55 | -2.53 | -5.53 | -21.57 | |
| Free Cash Flow | -84.3 | -58.46 | -37.34 | -43.61 | -69.82 | |
| Free Cash Flow Per Share | -1.27 | -1.42 | -1.75 | -5.55 | -17.73 | |
| Operating Margin | -1536.91% | - | -1377.14% | -3200.64% | -1912.33% | |
| Profit Margin | 1223.08% | - | -1548.23% | -3074.82% | -2831.20% | |
| Free Cash Flow Margin | -1448.47% | - | -1066.86% | -3084.37% | -2327.20% | |
| EBITDA | -86.9 | -62.21 | -45.91 | -42.16 | -54.12 | |
| D&A For EBITDA | 2.55 | 2 | 2.29 | 3.09 | 3.25 | |
| EBIT | -89.45 | -64.21 | -48.2 | -45.26 | -57.37 | |
| Effective Tax Rate | 0.14% | - | - | - | - | |
| Revenue as Reported | 5.82 | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.